Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489941 · ClinicalTrials.gov registry record · Phase 3
A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT03489941 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 65 participants.
The verdict
NCT03489941, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
Interventions
- DRUG Vehicle
- DRUG EM-100
- DRUG Zaditor®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2018-04-07 |
| Est. Completion | 2018-04-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03489941
The ClinicalTrials.gov registry entry for NCT03489941 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Vehicle is the first listed.
NCT03489941 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03489941 about?
NCT03489941 is a clinical study titled "A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle". A Single-Center study to demonstrate the non-inferiority of EM-100 to Zaditor® in the treatment of ocular itching.
What is the current status of trial NCT03489941?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2018-04-07. Estimated completion is 2018-04-29.
What interventions are being tested in trial NCT03489941?
The interventions under investigation include: Vehicle (DRUG), EM-100 (DRUG), Zaditor® (DRUG).
Who is sponsoring clinical trial NCT03489941?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.